Page 223 - Read Online

Douhara et al. Hepatoma Res 2017;3:215-20 Hepatoma Research
DOI: 10.20517/2394-5079.2017.32
www.hrjournal.net
Original Article Open Access

Efficacy and HCC development after DAA

therapy for patients with chronic hepatitis C:

a single center retrospective cohort study

Akitoshi Douhara, Hiroyuki Ogawa, Satoshi Nakatani, Takahiro Ozutsumi, Erika Shioyama, Masaaki Yoshikawa,
Shigehiko Ueda
Internal Medicine, Kokuho Central Hospital 404-1, Miyako, Tawaramoto-cho, Shiki-gun, Nara Prefecture 636-0302, Japan.

Correspondence to: Dr. Akitoshi Douhara, Internal Medicine, Kokuho Central Hospital 404-1, Miyako, Tawaramoto-cho, Shiki-gun, Nara Prefecture
636-0302, Japan. E-mail: aki-do@hotmail.co.jp

How to cite this article: Douhara A, Ogawa H, Nakatani S, Ozutsumi T, Shioyama E, Yoshikawa M, Ueda S. Efficacy and HCC development after
DAA therapy for patients with chronic hepatitis C: a single center retrospective cohort study. Hepatoma Res 2017;3:215-20.
ABSTRACT

Article history: Aim: The development of hepatocellular carcinoma (HCC) is reduced after interferon based
Received: 28 Jul 2017 treatment in patients with chronic hepatitis C (CHC). A new therapy using direct-acting
Accepted: 20 Sep 2017 antiviral agents (DAA) has been widely applied since 2014 for CHC. The purpose of this
Published: 17 Oct 2017 study is to investigate the efficacy, safety and development of HCC after DAA treatment.
Methods: The authors enrolled 33 consecutive patients who were treated with DAA for CHC
Key words: at the hospital between January 2015 and March 2016. The laboratory data were collected
Chronic hepatitis C, at the start and 24 weeks after DAA therapy. Results: The authors analyzed 33 patients
direct-acting antiviral therapy, (18 male, 15 female, mean age of 68-year-old). The hepatic C virus genotypes were type 1
development of hepatocellular (27 patients) and type 2 (6 patients). The number of patients treated with sofosbuvir (SOF) +
carcinoma, ledipasvir, daclatasvir + asunaprevir and SOF + ribavirin was 14, 13 and 6, respectively. The
sarcoidosis sustained virological response (SVR24) rate was 100%. Aspartate aminotransferase, alanine
aminotransferase and FIB4-index were significantly decreased after SVR24. Adverse effects
were observed in 9 patients (anemia, 5; liver function test disorder, 2; sarcoidosis, 1; pruritus, 1).
With regard to HCC development, one elderly patient (3.0%) had multiple HCC recurrence
after SVR24. Conclusion: DAA therapy achieved a high SVR24 rate with a good serological
response. However, one patient had multiple HCC recurrence. These findings indicate that
careful follow-up may be essential after DAA therapy.

INTRODUCTION (DAA) for patients with chronic CHC directly target
HCV replication and have been widely used globally
During the previous decades, Pegylated interferon since 2014. Compared to conventional IFN-therapy,
(PEG-IFN) plus ribavirin therapy for patients with chronic the sustained virological response (SVR) rate is higher
hepatitis C (CHC) cured hepatic C virus (HCV) infection and the side effects are reduced with DAA therapy.
in approximately 50% of treated patients . Emerging Previously, it was reported that IFN-based therapy
[1]
treatments with IFN-free direct-acting antiviral agents reduced the risk of liver complications, including the

Quick Response Code:
This is an open access article licensed under the terms of Creative Commons Attribution 4.0 International
License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
and reproduction in any medium, as long as the original author is credited and the new creations are licensed under the
identical terms.
For reprints contact: service@oaepublish.com

www.oaepublish.com © The author(s) 2017 215